Wugen is a startup based in the United States, most recent round Series B, 3 tracked investors.
Based in the United States, Wugen is a startup founded in 2018. Its most recent tracked round is Series B. Brouky records 3 investors associated with the company.
Wugen is a clinical-stage biotechnology company developing off-the-shelf CAR-T and NK cell therapies for the treatment of various cancers, including T-cell acute lymphoblastic leukemia and lymphoma.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.